Gemini Therapeutics' Chief Technology Officer. The license agreement grants Gemini Therapeutics exclusive rights to specific Avitide affinity resins for use in preclinical, clinical and commercial ...

Investors are always looking for stocks that are poised to beat at earnings season and Gemini Therapeutics, Inc. GMTX may be one such company. The firm has earnings coming up pretty soon ...

Investors in Gemini Therapeutics, Inc. GMTX need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 17, 2021 $5.00 Call had some of the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related ...

Gemini Therapeutics is bringing precision medicine and genomics to Dry AMD, a disease without an FDA-approved medicine. By focusing on CFH variants of Dry AMD, which represent over 6M patients in ...

CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular ...

Disc Medicine, a Watertown biotech firm developing drugs to treat blood disorders, plans to merge with Gemini Therapeutics, a struggling publicly traded biotech based in Wayland, the companies ...